In patients undergoing bone marrow transplant (BMT), reactive oxygen species (ROS) are released as a consequence of the events related to the preparative regimen. Total body irradiation (TBI), which is known to generate ROS, is a routine preconditioning procedure prior to BMT. Several studies have demonstrated that amifostine protects normal tissues. In the present report, we investigated the oxidative state of plasma and erythrocytes in 21 patients with hematological malignancies undergoing TBI. The dose fraction was 160 cGy, twice daily (eight sessions). For ROS detection, we used electron spin resonance spectroscopy and spin-trapping technique. In all, 15 patients received amifostine prior to the irradiation and six did not. No free radical signal was detected in the plasma samples spectrum of 15 amifostinetreated patients, and five of six samples of nontreated patients showed ROS signal. Only two of 15 treated patients had mucositis degree higher than 2, whereas five of six nontreated patients suffered this complication. The average hospitalization days in treated and nontreated patients were 23.5 and 29.7, respectively. This work represents an original observation; we found by direct measurements of free radicals that ROS are released during TBI, and confirmed the amifostine radical scavenger activity.
Summary:
In patients undergoing bone marrow transplant (BMT), reactive oxygen species (ROS) are released as a consequence of the events related to the preparative regimen. Total body irradiation (TBI), which is known to generate ROS, is a routine preconditioning procedure prior to BMT. Several studies have demonstrated that amifostine protects normal tissues. In the present report, we investigated the oxidative state of plasma and erythrocytes in 21 patients with hematological malignancies undergoing TBI. The dose fraction was 160 cGy, twice daily (eight sessions). For ROS detection, we used electron spin resonance spectroscopy and spin-trapping technique. In all, 15 patients received amifostine prior to the irradiation and six did not. No free radical signal was detected in the plasma samples spectrum of 15 amifostinetreated patients, and five of six samples of nontreated patients showed ROS signal. Only two of 15 treated patients had mucositis degree higher than 2, whereas five of six nontreated patients suffered this complication. The average hospitalization days in treated and nontreated patients were 23.5 and 29.7, respectively. This work represents an original observation; we found by direct measurements of free radicals that ROS are released during TBI, and confirmed the amifostine radical scavenger activity. Regimen-related toxicity (RRT) in bone marrow transplantation represents a major cause of mortality and morbidity. 1 Several mechanisms are related to the events causing RRT. The release of reactive oxygen species (ROS; superoxide, hydroxyl, peroxil and alkoxyl radicals and hydrogen peroxide) is known to cause tissue damage and could be implicated with other cytokines in generating these responses. [2] [3] [4] The production of these compounds, in addition to the possibility of the organism antioxidant defense, results in oxidative stress with the consequent cell damage.
Total body irradiation (TBI) has been used as a regular part of the conditioning regimen for BMT. One of the most important radiation-induced free radical species is the hydroxyl radical, which may be generated either directly by the radiation or by oxidation of water, or indirectly from other primary ROS converted to hydroxyl radicals by metabolic processes in the cells. This indirect radiation injury process is influenced by the cellular antioxidant status and is dependent on the antioxidant defense mechanisms. 5 TBI toxicity is associated to severe complications such as mucositis, interstitial pneumonitis, veno-occlusive disease, cataracts and growth delay in children. 6, 7 According to the traditional myeloablative conditioning regimen in BMT, effective TBI should include maximal tumor cell killing, immune suppression and the required 'space' for the new hematopoietic organ, with minimal injury to normal tissue. In the past, two strategies have been used for improving the therapeutic index of the radiotherapy (toxicity in the tumor/toxicity in healthy tissues), 1 -administration of radiosensitizers or 2 -the administration of radioprotectors.
Several studies have demonstrated that amifostine (a phosphorylated thiol:S-2 [3-aminopropylamino]-ethylphosphorothioic acid), administrated before radiation, protects normal tissues from radiation damage [8] [9] [10] without attenuating its antitumor effect. [11] [12] [13] Amifostine is a pro-drug, the radio protective effect of which is based on the presence of a thiol group in its active metabolite (S-2 [3-aminopropylamino]-ethanethiol). In the plasma, amifostine is rapidly dephosphorylated (by membrane-bound alkaline phosphatase enzymes) and enters the cells as its active form. 14 It may be that the selectivity for normal tissue, that is, rapid uptake into normal tissues and slow-to-negligible uptake in tumor cells, is a result of the decreased vascularity of tumors, decreased activity of alkaline phosphatase enzymes in tumor cells and pH dependence activity of the active drug. It is known that the in vitro amifostine antioxidant activity shows scavenging activity against lipoperoxidation and against the highly reactive hydroxyl radical. 15 Pharmacokinetic data show that amifostine is cleared in the patient's plasma with a half-life of about 10 min, and that the active drug concentration in the blood cell fraction is similar to that of plasma. 16 We have used amifostine to prevent toxicity related to TBI, and compared these results with similar patients not receiving the drug, in a retrospective analysis. In order to evaluate the radioprotective effect of amifostine treatment during TBI, we investigated the oxidative state of plasma, the response of the red blood cells to an oxidative insult and the presence of ROS in plasma. For its detection, we used an ex-vivo spin-trapping technique with a-phenyl-N-t-butyl nitrone and electron spin resonance spectroscopy.
Materials and methods

Patients
In total, 21 patients with hematological malignancies were studied. All of them received TBI and cyclophosphamide as the conditioning regime for BMT. The diagnoses were: seven chronic myeloid leukemia, five acute myeloid leukemia and five acute lymphoblastic leukemia, four others. The mean age was 32 years (7-53). The femalemale ratio was 15:6. Nine patients received an allogeneic transplant from an HLA-identical sibling, and 12 received an autologous BMT. Cyclosporine and short-course methotrexate amifostine was used in 15 patients. In six patients without the amifostine treatment, the same measures were obtained. Amifostine was given by intravenous infusion 30 min before each radiotherapy session, at a dose of 340 mg/m 2 . Vital signs were controlled every 10 min to detect hypotension, nausea and vomiting. TBI was carried out with a 15 MV lineal accelerator, using a dose fraction of 160 cGy twice a day for 4 days (total dose: 1280 cGy). The dose rate was 16 cGy/min. After eight sessions of TBI, all patients received cyclophosphamide in doses of 60 mg/kg/day, during two consecutive days. Patients gave their consent prior to the conditioning.
Blood pool of healthy donor volunteers
We used a blood pool of healthy donor volunteers (a) in the study of the amisfostine activity as a scavenger of free radical present in plasma (in vitro study), (b) as normal samples, in the test of oxidative treatment of erythrocytes for lipid peroxidation quantification, (c) in the test of plasma antioxidant capacity; the washed erythrocytes of this pool were incubated with the plasma of the patients to be used as targets of the oxidative injury.
Chemicals
All reagents, Tert-butyl-hydroperoxide, sodium azide, sodium dodecylsufate, 4-maleimido tempo and a-phenyl-N-t-butyl nitrone (Sigma), thiobarbituric acid (Fluka), ethyl acetate (Merck) and bovine albumin (Roth), etc, had analytical grade.
In vitro study
Scavenging of a stable free radical. The direct measurement of the partial consumption of a stable free radical by electron spin resonance allows to obtain information regarding the quantity of the antioxidant present in the sample. 17, 18 When a stable free radical is reduced to a hydroxylamine, its signal intensity decreases because this compound cannot be detected by electron spin resonance. Using the stable free radical 4-maleimido tempo (final concentration 30 mM), we studied the samples under different conditions, using a flat quartz cell and recording their spectra in an electron spin resonance spectrometer (ECS 106 Bruker) at room temperature. The microwave frequency used was 9.66 GHz, the microwave power was 20 mW, the modulation frequency was 50 kHz, the field center was 3445 Gauss, the sweep width was 100 Gauss, the time constant was 82 ms, and the modulation amplitude was 0.289 Gauss. Since the spectral line shape was identical between samples, we could measure the peak height as a direct function of the radical concentration. The effect of the amifostine presence and the influence of its concentration on the signal intensity were studied in saline buffer and by adding amifostine to final concentrations of 170 and 340 mM.
The time course of free radical relative signal decrease was analyzed in saline buffer, plasma, saline buffer þ bovine albumin at a final concentration of 10 g/l, plasma þ bovine albumin at the same final concentration, and plasma þ amifostine at a final concentration of 340 mM.
The radical consumption increases and the signal intensity decreases as a function of time. Therefore, the ratio (peak height at time t/peak height at time t ¼ 0) Â 100 decreased proportionally to the radical concentration. Among the three picks of the signal (Figure 1 ), the height of the last one was selected to be measured (h-1 pick or high field pick).
Ex vivo study Samples. For the group of patients treated with amifostine, the blood samples were drawn during the treatment in the following sequence: (a) basal, (b) post amifostine, (c) post irradiation (doses 1-7), and (d) after BMT (between the 3rd and 9th days after transplantation). For the group of patients without amifostine, the sequence was: (a) basal, (b) post irradiation (doses 1-7), (c) after BMT (between the 3rd and 9th days after transplantation). The blood samples were centrifuged immediately after being obtained at 3000 rpm for 5 min.
Plasma was removed and fractionated in two parts. One part was frozen at À201C and stored until the study of plasma antioxidant capacity was performed. The other part was immediately diluted (1:1 v/v) with a spin trap solution (a-phenyl-N-t-butyl nitrone in saline buffer 30 mM final concentration (prepared prior to use). The spin adduct formed was extracted with ethyl acetate, immediately separated from the aqueous phase and frozen at À201C until the detection of ROS by electron spin resonance spectroscopy, within the next 2 or 3 h, was performed.
Erythrocytes were washed three times with saline buffer and used as target for the oxidative treatment with t-butylhydroperoxide. Quantification of the membrane lipid peroxidation was made through the quantity of the thiobarbituric acid reactive substances produced.
Detection of ROS
Free radicals (R ) are chemical compounds having one unpaired electron. This allows its detection by electron spin resonance spectroscopy. Unfortunately, in biological samples, it is not always possible to observe the free radicals directly, since usually they have a very short lifetime and their concentration may be below the limit of detection by electron spin resonance spectrometers. The technique of spin trapping provides a means to overcome these problems. It involves the addition of a spin trap that reacts with the free radical (the spin), giving rise to a relative longlived free radical product (the spin adduct), which may be studied by spin resonance spectroscopy during an adequate period.
The extraction of the a-phenyl-N-tert-butyl nitrone spin adduct in ethyl acetate in order to increase its half-life time and the detection of its electron spin resonance spectrum have been described in previous reports in animal models 19, 20 and in human blood. 21 The ethyl acetate extracts were transferred to a flat quartz cell and spectra were recorded.
Red blood cells' oxidative stress
The aim of this test is to evaluate the erythrocyte resistance against an oxidative treatment.
Oxidative treatment of erythrocytes. (i) Red blood cells were washed three times with saline buffer. (ii) The washed cells were suspended in saline buffer 50% (v/v) and incubated at 371C with an oxidizer. T-butyl-hydroperoxide (3 mM final concentration) was used as an oxidizer, which has frequently been used as a model compound to initiate radical formation in biological systems. 22 (iii) Samples of these suspensions were taken at 0 and 60 min of incubation time. Proteins were eliminated from these samples by adding hydrochloric acid (1 N) and trichloroacetic acid (20% v/v), and centrifuged at 2000 rpm for 10 min. (iv) Supernatants were removed and used for the measurement of thiobarbituric acid reactive substances, commonly known as TBARS (mainly aldehydes arising from lipoperoxidation). 23 Normal samples (red blood cells from a blood pool of healthy donor volunteers), used as control, were processed simultaneously.
Quantification of lipid peroxidation. TBARS were measured as an index of the erythrocyte oxidative insult produced during the incubation with the oxidizer (IIa); high TBARS concentration is an index of high lipoperoxidation, and consequently less erythrocyte capacity to avoid the effects of oxidative treatment. TBARS concentration was determined by a colorimetric reaction adding to the supernatants of the erythrocytes oxidative treatment with sodium dodecylsulfate 10%, butylated hydroxy toluene 13.4 mM in ethanol and thiobarbituric acid 0.7%. Mixtures were incubated for 15 min in a boiling water bath and, after cooling, the absorbance at 532 nm was recorded in a Shimadzu UV 210 double-beam spectrophotometer. Results were given as TBARS concentration produced per milliliter of patient erythrocytes. 24 
Plasma antioxidant capacity
This test shows the plasma capacity to protect erythrocytes against an oxidative treatment. The reaction was carried out with a similar technique as in the case of the oxidative treatment of erythrocytes study. Instead of patients' red blood cells, the technique used normal red blood cells (from a blood pool of healthy donors) added to the plasma of the studied patients, in a volume ratio 3:1 (packed normal red cells/patient plasma). In samples used as a control, the buffer replaced plasma.
Plasma antioxidant capacity was estimated as a percentage of inhibition of erythrocyte oxidation because of the presence of plasma. Control samples (erythrocytes without plasma) were considered as 100% of oxidation and the ratio used was ((TBARS concentration in patient samples/ TBARS concentration in control sample) Â 100). Values were expressed as individual data72s.d. The s.d. was calculated from the TBARS method parameters.
Results
Patients tolerated the entire procedure with the expected toxicity for BMT. Amifostine administration caused nausea and vomiting in 13 out of 15 patients responding to usual antiemetic drugs. Only one patient had hypotension, requiring withdrawal of amifostine infusion. 25 In the group of patients treated with amifostine, only 2/ 15 patients had mucositis higher than grade 2, whereas in the group of nontreated patients 5/6 suffered this complication (toxicity was graded according to WHO).
The average hospitalization days in the treated and the nontreated group were 23.5 (18-36) and 29.7 (23-37), respectively. No differences for other toxicities, overall survival or relapse rate were observed.
Biophysical and biochemical study
In vitro. Figure 1 shows a typical spectrum of the nitroxide radical 4-maleimido tempo, with its three picks at different values of magnetic field. The height of the last pick (h À1 pick) was selected to be measured as a direct function of the radical concentration.
4-maleimido tempo is a stable free radical in water solution; thus, its solution in buffer does not exhibit any variation of the electron spin resonance signal as a function of time. Figure 2 shows the effect of adding two different doses of amifostine. The relative intensity of the signals (h À1 amifostine þ buffer/h À1 buffer) showed a dose-dependant decrease.
The 4-maleimido tempo relative signal as a function of time, in different chemical situations, is shown in Figure 3 . The time course of a stable nitroxide radical may be used in the evaluation of the radical scavenger capacity of the sample. Radicals are potent oxidizers. Plasma has antioxidant capacity and albumin is a plasma component that has antioxidant activity. This figure shows that in buffer the signal remained constant, it does not have antiradical activity; in a buffer solution of albumin and in normal plasma, the relative signal decreased due to the albumin and plasma antiradical activity; in plasma supplemented with albumin or with amifostine, the signal decreased more than in plasma, these increased in the basal plasma antiradical activity showed that both compounds have antiradical activities. Figure 4 shows the electronic spin resonance spectrum of the spin adduct obtained from: All spectra were drawn to the same scale (the vertical axis was calibrated in arbitrary units). (b-d) spectra were similar to the negative control. They did not show detectable ROS. Similar spectra were obtained for all patients treated with amifostine. Figure 5 is similar to Figure 4 , but corresponds to a patient nontreated with amifostine. It shows the spectra of: Similar spectra were obtained in five of the six patients analyzed.
Ex vivo. (I) Detection of ROS:
(II) Red blood cells oxidative stress: The average value of control TBARS concentration, performed with 30 nonirradiated volunteers was 3.3971.03 nM. The TBARS concentrations for treated patients were maintained within the control values, approaching the mean value during the treatment sequence. Nontreated patients maintained their initial TBARS concentration, which was somewhat higher than normal, even though no statistical analysis was possible, owing to the low number of patients ( Figure 6 ).
(III) Plasma antioxidant capacity: Plasma antioxidant capacities (PAC) are shown in Table 1 . The TBARS ratio between patient and control decreases for all patients with amifostine treatment. For a nontreated patient, even though the initial value is close to control, after TBI and BMT treatments, the TBARS ratio is increased. A similar tendency was found for all the patients who had not received amifostine.
Discussion
ROS may be an important clinical tool to assess and quantify the degree of damage caused by ionizing radiation. In this TBI experience, we observed the presence of ROS in the plasma of patients undergoing BMT.
TBI is a field of interest for the evaluation of some radiation toxic effects such as severe mucositis, its relationship with ROS production and the possibility of an effective blockade of their effects in order to improve the morbidity and mortality of this procedure.
In the in vitro experiments, using a stable free radical as spin probe, we confirmed the amifostine free radicalscavenging properties.
The amifostine effectiveness for radioprotection has been evaluated previously by other authors in different cancer types, 9, 12, 26, 27 but none of them used a direct technique for free radical measurement.
The techniques of in vitro and in vivo spin trapping using a-phenyl-N-t-butyl nitrone as trapper are well known. 17, 18 In this study, amifostine was used as an antiradical treatment. After TBI, no radical adducts signal was detected in the plasma samples spectrum of 15 amifostinetreated patients, and five of six plasma samples of nontreated patients showed adducts signal in a similar situation.
In the analysis of the erythrocytes oxidative stress data, according to our results and in agreement to previous papers, 28, 29 it may be concluded that erythrocytes are not significantly affected by the radiation levels at which the patients were submitted. Their behavior was similar in both groups of patients.
With regard to plasma antioxidant capacity, we found a favorable evolution in treated patients. TBARS ratio at the end of our study was similar to control value. With amifostine, TBARS levels decrease, and consequently the plasma antioxidant capacity increases. We can see this effect after drug administration, on the following days of treatment. Meanwhile in the other group, the nontreated patients, the tendency was the opposite: the TBARS ratio increased along the treatment; it shows a decrease in the plasma antioxidant capacity. This work represents an original observation. We found by direct measurements of free radicals that ROS are released during TBI. We also confirmed the amifostine radical scavenger activity in vitro and in vivo, which may explain its radio-protective action and the decrease of the adverse radiotherapy effects.
Although the number of patients is small, it can be estimated that the presence of this drug in plasma during TBI administration may act as a protective agent. The decrease of the number of patients with severe mucositis and the decrease of hospitalization days in the group of patients treated with the drug also are an index of its protective action.
